Recipharm and LIDDS Sign Contract
News Dec 17, 2015
Recipharm and LIDDS have signed an exclusive collaboration agreement regarding scale-up of the production process and commercial manufacture of Liproca® Depot, LIDDS patented targeted treatment for prostate cancer.
The agreement will be an important component for the upcoming Phase IIb study which is planned to start in 2016. In connection with the agreement, Recipharm invests SEK 5 million in a private placement, thus becoming the third largest shareholder of LIDDS.
“LIDDS’ technology platform is highly interesting as it potentially can be used for other, already approved therapies which may lead to shorter development time for new products. We are looking forward to collaborating with LIDDS through contributing our technical expertise within production, and thus delivering a more gentle treatment for prostate cancer patients in the future”, says Carl-Johan Spak, EVP Development & Technology at Recipharm.
“We are very pleased that the agreement with Recipharm has been signed, as it is an important part of the preparations for the next clinical study. Recipharm is a well-reputed company with high quality, cost-effective processes for manufacturing. In addition, Recipharm has extensive experience collaborating with different types of organizations across the world. This agreement will strengthen the attraction for out-licensing of Liproca® Depot”, says Monica Wallter CEO of LIDDS.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Anti-Malaria Drugs Delivered With CaffeineNews
Many drug delivery systems, such as capsules and tablets, can be difficult to swallow, especially for children. Making delivery systems out of polymer gels is an attractive option, but usually requires hazardous levels of heavy metals to be used. Now, scientists have found a way to build these gels from caffeine molecules.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018